

CONFIDENTIAL

EVENT SPONSORSHIP AGREEMENT

This sponsorship agreement (“**Agreement**”) is effective as of the [24 of March 2025] (“**Effective Date**”) and is entered by and between:

BeiGene International GmbH - Denmark Branch

a company incorporated under the laws of Switzerland whose registered office is at c/o TMF Denmark, Købmagergade 60, DK-1150 Copenhagen K, Denmark CVR 42790516 (“**BeiGene**”)

and

Patientforeningen for Lymfekræft, Leukæmi og MDS a non for profit institution incorporated under the laws of Denmark whose registered office is at Denmark Banetoften 26, 4700 Næstved (“**PAG**”)

WHEREAS, BeiGene is a biotechnology company that develops and commercializes biopharmaceutical products;

WHEREAS Company is a non-for profit or profit organization that wish to organize the event described in Annex 1 of the Agreement (“**Event**”) and has requested funding support.

WHEREAS PAG has engaged the Company for the organization and realization of the Event. Company will be in charge of all the activities that are required for the realisation of PAG’s Event.

WHEREAS BeiGene after receiving PAG’s request, which is attached as annex 1, has agreed to provide support to the Company for the for the organization and realization of PAG’s Event as described below.

PAG, Company and BeiGene may each be referred to individually herein as a “**Party**” and collectively as the “**Parties**.”

NOW THEREFORE in connection therewith and in consideration thereof, PAG, Company and BeiGene agree as follows:

1. BeiGene will provide Company with Twenty thousand (20.000) DKK (“**Support**”) which shall be exclusively used by Company for the organization and realization of PAG’s Event which is described in Annex 1 and BeiGene will receive the sponsorship benefits described hereinbelow.

Event Details

Title of Event: Theme Day on Lymphoma, Leukaemia and MDS.

Date of Event: 5 of April 2025

Location of Event: Scandic, Sluseholmen, Copenhagen, Denmark

Sponsorship Benefits

CONFIDENTIAL

BeiGene will be entitled to the following sponsorship benefits: BeiGene will be listed as sponsors and the opportunity to participate in the whole day meeting

2. Payment of the Support shall be made by BeiGene to the bank account of the Company provided to BeiGene in writing within forty-five (45) days of the Effective Date of this Agreement. The invoices must display any applicable VAT amount separately.
3. PAG shall transparently disclose that BeiGene has provided Support for the Event. BeiGene shall have the right to publish the name of PAG and the details of the Support and Event, in order the name of the Company as recipient of the Support, in order to comply with transparency reporting requirements. Such reporting may include the name of any relevant healthcare professional (HCP) who was a presenter at the Event and was paid at fair market value for his or her contribution to the Event.
4. BeiGene shall have no control or influence over the content of the Event. BeiGene does not agree, recommend, obtain or otherwise provide any details of the attendees that will participate in the Event.
5. The Parties agree that the Support and the sponsorship are not being provided by BeiGene, nor accepted by the PAG or the Company, as an inducement to, either now or in the future, purchase, prescribe, promote, or recommend any of BeiGene's products or services.
6. PAG has entrusted the Company with the organization of the Event and the management of any related economic and administrative activities delegated by PAG to the Company. PAG remains responsible for the fulfilment of the obligations undertaken with this Agreement towards BeiGene.
7. No part of the Support may be paid to any third party, other than as reasonable fair market value compensation for items and services obtained at fair market value provided to PAG by the Company in connection with the Event in accordance with applicable laws, regulations and applicable industry codes of practice (including those pertaining to transparency reporting).
8. No portion of the Support shall be used by the Company to provide unlawful benefits to a healthcare professional or to any government employee or official. PAG and the Company represent and warrant that no person or company working on behalf of PAG or the Company, shall directly or indirectly, offer, pay, promise to pay, or authorize such offer, promise or payment, of anything of value, to any person or entity for the purposes of obtaining or retaining business or any improper advantage in connection with this Agreement, or that would otherwise violate any applicable laws, rules and regulations concerning or relating to public or commercial bribery or corruption.
PAG and the Company agrees to comply with all the regulations relating to Anti-Bribery, including the OECD Anti-Bribery Convention and the United States Foreign Corrupt Practices Act, as amended from time to time, with regard to the Event including not offering or giving anything of value to a foreign public official in connection with the performance of the official's duties or inducing an official to use their position to influence any acts or decisions of any foreign, state or public international organization.
9. PAG is free to seek funding from other companies. If any additional funding reaches a level such that all or part of the Support is no longer required by PAG, the Company shall refund such amount of the Support that

CONFIDENTIAL

is no longer required. The Company shall return any unused funds provided by BeiGene or any amounts not used in accordance with the terms and conditions of this Agreement:

- within 30 days from the date of the Event or;
- within 30 days from the cancellation of the Event or;
- within 30 days from termination by BeiGene of the Agreement for PAG's and/or Company's breach of the obligations contained in the Agreement.

10. Any discussion of medicinal therapies or test/quizzes/votes concerning Continuing Professional Development (CPD) at the Event shall be non-promotional, balanced, accurate and complete and shall comply with applicable laws and regulations
11. The questionnaire as described in annex 1, will be reviewed by health care professionals.
12. PAG confirms that the selection of the location and timing of the Event is based on one of the following criteria: (i) the majority of the attendees are resident in the country where the Event will take place, or (ii) the attendees at the Event are coming from different countries and, therefore, the Event was selected based on logistical convenience considering the country of residence of the attendees.
13. In the event PAG or the Company becomes aware of an adverse event and/or a product complaint, PAG or Company shall inform BeiGene's Safety Operations Group within 24 hours of first becoming aware via adverse_events@beigene.com and/or productcomplaints@beigene.com.
14. PAG and the Company shall keep and maintain until ten (10) years after the Event have been completed full and accurate records relating to (i) the Event and the Support; (ii) all expenditure reimbursed by the PAG and (iii) all payments to any third party (HCPs included) made by the PAG in connection with this Agreement.
To ensure compliance with any applicable laws and regulations by BeiGene, PAG shall promptly on request afford BeiGene or BeiGene's representatives' access to all records relating to (i), (ii) and (iii) above at BeiGene's expenses. Such records shall be made available to BeiGene during normal business hours at the PAG's office or place of business or, in the event that no such location is reasonably available, via email.
15. The Parties will process all personal data (as defined in applicable data protection laws) obtained during the course of the Event in accordance with the applicable data protection laws.

BeiGene will only process any personal data received from PAG and the Company in order to enter into or perform this Agreement. PAG warrants that it shall limit the personal data disclosed to BeiGene to the contact information for individuals involved with this Agreement and shall inform or obtain the prior written consent of each individual, as required by applicable law, for the disclosure of their respective personal data to BeiGene and processing in accordance with this clause. The parties understand that BeiGene will not have any further information/consent obligations towards the Company's and PAG's personnel.
16. This Agreement shall commence on the Effective Date and shall automatically terminate two (2) months from the date of the completion of the Event.

CONFIDENTIAL

17. In the event of a conflict between the provisions in the main body of this Agreement and any annex or attachment hereto, the provisions of this Agreement will control.
18. The Parties agree that this Agreement will be governed by and interpreted under the laws of Denmark. Any dispute arising out of this Agreement shall be submitted to the exclusive jurisdiction of the competent courts of Copenhagen, Denmark,
19. This Agreement may be executed in counterparts all of which taken together shall constitute one agreement and copies may be exchanged electronically (including with DocuSign), such as by e-mail (e.g. PDF) and such electronic copy of the signed document will be considered valid and binding on the signing Party.

BeiGene International GmbH - Denmark Branch

DocuSigned by:
Astrid Ottosson Wadlund
902BE8EDF5D84AE...

Name (CAPS): ASTRID OTTOSSON WADLUND

Title: Medical Director Nordics

Date: 24-Mar-2025

Patientforeningen for Lymfekræft, Leukæmi og MDS

Signed by:
Rita O. Christensen
F92DBD4EBA834E6...

Name (CAPS): RITA O. CHRISTENSEN

Title: Chair

Date: 24-mar-2025

CONFIDENTIAL

Annex 1 - Original Request for Support/Sponsorship Benefits

Næstved, 6 March 2025

Application for funding to organise a Theme Day in April 2025 on Lymphoma, Leukaemia and MDS.

We hereby apply to Beigene Danmark for DKK 20,000 to support the organisation of a Theme Day on 5 April at Scandic, Sluseholmen in Copenhagen.

Background to the application

As a patient organisation, LyLe's overall purpose is to collect and disseminate information for the benefit of patients, relatives and other interested parties. LyLe is an organisation that is close to its members - patients and relatives - and the association's theme meetings are an important part of this endeavour. With the theme meetings, which in principle are open to everyone, we emphasise what is close and relevant to everyone connected to blood cancer. LyLe also wants to build and maintain close ties with the haematology departments at the major hospitals.

The theme days are attended by patients and relatives who are typically affected by what we consider to be the main diseases. We therefore emphasise that we can hold sessions on the theme day where invited haematologists give presentations on the diseases that they deal with in their daily work. This will typically be:

- CLL
- CML
- Lymphatic cancer
- MDS/AML

We will emphasise understanding of the disease, treatment strategies and future treatment options. We will also focus on Secondary Immune Effect, GVHD, Car-T, any research projects we support in the association.

CONFIDENTIAL

Our experience shows that these disease-specific sessions are important for the participants, who are inherently seeking knowledge about the disease they are suffering from. Sessions are also a good opportunity for participants to ask questions that relate to their own disease and treatment

Our website and magazine publications are also an important part of the association's information sharing and are highly sought after by our members. The magazines are also a way of strengthening the association's ties with the haematology departments at the large hospitals, as the magazines are distributed to the departments so that they are also available to patients with lymphoma, leukaemia and MDS and their relatives.

We maintain our level of ambition as before.

Our goal is to organise thematic meetings and subsequently publish member magazines this year and continuously update and expand our website, lyle.dk.

We seek support from the pharmaceutical industry, various foundations and funding programmes, such as Tips-og Lottomidlerne. We emphasise the importance of obtaining support from a variety of sponsors for each of our projects.

Project description

The application includes the organisation of a theme meeting and editorial work for use in the publication of LyLe Fokus and for use on lyle.dk and groups on Facebook and Twitter to the extent that it is current and relevant. The application also includes production.

LyLe's regional theme meetings are an expression of the association's desire to be as close as possible to where its members are by holding meetings of approximately 7+ hours in collaboration with the association's established local network groups and the regional haematology specialist centre.

The overall aim of the organisation is to always innovate and adapt to current issues in both disease knowledge and treatment to meet the needs and wishes of its members. At each themed meeting, there will be separate sessions for each disease area, and we always listen to the wishes of patients and their relatives.

CONFIDENTIAL

Based on the knowledge LyLe possesses about the wishes and needs of its members, there will be a special focus on the following main themes in collaboration with various speakers:

- Having a haematological disease - latest research findings
- Existing and future treatment options like Car-T
- Focus on blood cancer, late effects and working life
- There will also be a focus on a number of specific diseases as mentioned above

Target audience: The meeting is open to everyone, but is especially aimed at blood cancer patients and their relatives, but healthcare professionals and partners are also welcome. We expect that there will be participants at each meeting.

Time and place: The meeting will be held on 5 April in Copenhagen, Scandic Sluseholmen, invitation to come later. In connection with the meeting, we will also hold the association's annual general meeting.

Speakers and debate: Four doctors from the field of haematology. This time we will also focus on "secondary immunodeficiency" and on research in various areas of haematology. More info will follow later.

As an organisation, we will be represented by local coordinators from the network groups, chairman, board, secretary, photographer and editor/journalist

Budget

See next page.

Contract/cooperation agreement

LyLe complies with enli.dk rules on cooperation between the pharmaceutical industry and patient organisations as well as its own internal code of ethics (attached), which entails entering into a contract/cooperation agreement and publishing it on the association's website, just as sponsors will be disclosed for each issue of Lyle Nyt.

Næstved, 6 March 2025

CONFIDENTIAL



Rita O. Christensen
Chairman of the board

Budget

As shown in the attached budget, an estimated number of participants is stated, but the possibility of increasing the number of participants as needed will be agreed with the various locations. An increased number of participants will obviously result in a proportional additional cost compared to the budgeted amount.

The budget for the theme day in Copenhagen is incl. VAT.
Lyle cannot deduct VAT as we are a voluntary organisation.

- | | |
|---|------------|
| - Advertising in relevant media, including advert development | 15,000 DKK |
| - Organisation of the events, estimated number of participants: 50 people | |
| - Administration including online registration and payment | 9.500 DKK |

CONFIDENTIAL

- Room hire and light catering	70,000 DKK
- Fees for speakers etc.	15.000 DKK
- Transport costs	5,000 DKK

<u>Total for theme day incl. VAT</u>	<u>114.500 DKK</u>
---	---------------------------

LYLE pays for itself and is responsible for the speakers' fees.

The event is sponsored by several pharmaceutical companies.

The professional programme and content is determined by LYLE and the speakers independently of the sponsors.